What Is Genitourinary Syndrome of Menopause?

Genitourinary syndrome of menopause, or GSM, is the current medical term for the collection of vaginal, urinary, and sexual symptoms that develop when estrogen levels drop during and after menopause. It affects a large majority of postmenopausal women, with one Spanish study of over 500 postmenopausal women finding a prevalence of about 70%.
¹ Unlike hot flashes, which tend to fade over time, GSM generally gets worse without treatment, and there are more options for managing it than many people realize.

What the Term Actually Covers

Before 2014, doctors called this condition “vulvovaginal atrophy,” a name that focused narrowly on the vagina and that many women found off-putting. A joint consensus conference between two major menopause societies agreed that “genitourinary syndrome of menopause” was more medically accurate and publicly acceptable, because the condition involves far more than just the vagina.² GSM can include changes to the labia, clitoris, vaginal opening, vagina itself, urethra, and bladder. The symptoms fall into three overlapping clusters:

Genital symptoms: dryness, burning, and irritation of the vulva and vagina.
Sexual symptoms: poor lubrication during sex, pain or discomfort with intercourse, and diminished arousal or function.
Urinary symptoms: urgency, painful urination, and repeated urinary tract infections.

Not every woman gets all of these. In the GENISSE study of postmenopausal women in Spain, vaginal dryness was the most commonly reported symptom at about 93%, followed by reduced lubrication during sexual activity at 90%. On physical exam, decreased vaginal moisture and loss of the natural folds (rugae) in the vaginal wall were the most common findings.³ But the same study also found GSM significantly linked to stress or mixed urinary incontinence and overactive bladder, reinforcing why the broader name matters.

What Happens to the Tissue and Why

The vulva, vagina, urethra, and bladder all contain estrogen receptors, which is why falling estrogen has such a wide reach. Research using bladder tissue has confirmed that estrogen receptor proteins are present in both the vaginal-type lining and the bladder’s own transitional lining.⁴ Progesterone receptors are also present across the pelvic floor, and levels of one key type drop significantly after menopause.⁵

When estrogen withdrawal hits these tissues, several things happen at once. The tissues lose collagen and elastin, smooth muscle cells start functioning differently, and blood vessels become fewer, all leading to thinner walls, reduced blood flow, and less elasticity.⁶ In the vagina, this translates to a drier, more fragile lining that is easily irritated. In the urethra and bladder, it can mean weaker mucosal defenses and a lower threshold for infection.

The Vaginal Microbiome Shift

One of the less obvious but most consequential changes involves the vaginal ecosystem. Before menopause, estrogen drives vaginal cells to produce glycogen, which feeds Lactobacillus bacteria and keeps the vaginal environment acidic. After menopause, free glycogen drops sharply. One study measuring this directly found that postmenopausal women had dramatically lower free glycogen levels, and that Lactobacillus counts tracked closely with glycogen in both pre- and postmenopausal groups.⁷ The postmenopausal group also had a higher vaginal pH (median 4.6 versus 4.0), reflecting this loss of acid-producing bacteria.

A less acidic vaginal environment is not just an abstract lab measurement. The higher pH makes the vagina more hospitable to pathogens that would otherwise struggle to survive, and this microbiome shift contributes directly to many GSM symptoms.⁸ It also helps explain why recurrent urinary tract infections become so much more common after menopause: changes in the urogenital lining and microbiome go hand in hand.⁹

Why So Many Women Suffer in Silence

Despite how common GSM is, the condition is dramatically undertreated. In the GENISSE study, about 60% of women found to have GSM on examination had never been given that diagnosis.¹⁰ A qualitative study exploring patient perspectives found several barriers: women were often unclear about which symptoms vaginal estrogen was meant to treat, how to apply it, and how it differed from systemic hormone replacement therapy. Cost, lack of insurance coverage, and fears about cancer all contributed to reluctance.¹¹

Shame plays a role too. Research on screening practices has noted that societal beliefs around sexual health discourage both patients and clinicians from raising the subject.¹² A study during the COVID-19 pandemic found that about two thirds of women with GSM had never discussed sexuality with their gynecologist, and treatment adherence was poor in nearly three quarters of those asked about it during lockdown.¹³ The pattern is clear: even when women are prescribed something that works, many stop using it, and those who never bring it up never get treated at all.

First-Line Treatment Without Hormones

For mild symptoms, or when hormone use raises concerns, vaginal moisturizers and lubricants are considered the starting point. Moisturizers are used regularly (typically several times a week) to restore moisture in the vaginal lining, while lubricants are applied during sexual activity to reduce friction and discomfort.¹⁴ For breast cancer survivors in particular, these products are recommended as first-line therapy.

Not all over-the-counter products are equally safe. A review of vaginal lubricants and moisturizers found enormous variation in their chemical composition, with some products having an unphysiological pH or osmolality that can damage the vaginal lining. The general recommendation is to choose products that closely match the body’s own vaginal secretions in terms of pH and osmolality, and to avoid ingredients known to be irritating.¹⁵ Lubricants and moisturizers can also be used alongside hormonal treatments when a woman finds that one approach alone is not enough.

A promising non-hormonal alternative is vaginal hyaluronic acid. A pilot trial comparing it directly to vaginal estrogen found no meaningful difference in symptom improvement after 12 weeks: scores on validated questionnaires, sexual function measures, and vaginal pH all improved in both groups, and over 90% of participants in both arms reported feeling better.¹⁶ The study was small and would need to be replicated, but for women who cannot or prefer not to use estrogen, hyaluronic acid is worth discussing with a provider.

Pelvic floor physical therapy is another non-hormonal tool. Treatment guidelines include it alongside moisturizers and behavioral therapy, particularly for women who develop pelvic floor muscle tightness in response to chronic pain during sex, which can worsen the cycle of discomfort.¹⁷

Local Estrogen Therapy

When symptoms are moderate to severe, local estrogen applied directly to the vagina is generally considered the gold standard.¹⁸ Local estrogen comes in several forms, including creams, tablets, and rings, and all are effective at relieving symptoms. A head-to-head trial found that vaginal estradiol tablets and conjugated estrogen cream provided equivalent relief of dryness, soreness, and irritation.¹⁹

The practical differences between formulations matter. In that same trial, significantly more patients using the tablet rated their medication favorably compared to those using the cream, and the dropout rate was much lower with the tablet (about 10% versus 32%). The cream also caused more systemic estrogen absorption, meaning more of the hormone leaked into the bloodstream, and led to more cases of endometrial thickening.²⁰ A separate study in Iran confirmed that while both forms worked equally well, the tablet caused fewer hygiene complaints (0% versus 23%) and patients found it significantly easier to use.²¹

How Safe Is Local Estrogen for the Uterine Lining?

One of the biggest fears patients have about vaginal estrogen is endometrial cancer. This concern is largely misplaced for low-dose formulations. A systematic review of 20 randomized controlled trials involving nearly 3,000 women on vaginal estrogens found rates of endometrial cancer and hyperplasia of 0.03% and 0.4% respectively, which are consistent with background rates in the general population.²² An exception was conjugated estrogen cream at a higher dose (1.25 mg), where hyperplasia appeared to be more than sporadic.

A review of systemic absorption with low-dose and ultra-low-dose vaginal estrogen products found that circulating estradiol levels remained low to negligible, though the amount of absorption could vary somewhat depending on the product and how it was placed.²³ The consensus among menopause experts is that low-dose vaginal estrogens do not substantially raise the risk of endometrial problems, though data on very long-term use are still limited.²⁴ For most women, this means that using a vaginal estrogen tablet or ring at the recommended dose does not require adding a progestogen to protect the uterus, as you would with systemic hormone therapy.

Other Prescription Options

Two additional prescription approaches fill important gaps. Ospemifene is an oral medication that acts on estrogen receptors selectively, meaning it can behave like estrogen in some tissues and block estrogen in others. In the vagina, it acts as an estrogen agonist, improving vaginal structure, lowering pH, and reducing pain with sex. Preclinical data showed it reduces breast cell proliferation, and safety data through a year of treatment showed minimal impact on the endometrium.²⁵ Ospemifene’s main appeal is that it is a pill you swallow rather than something you insert vaginally, which some women strongly prefer.

Intravaginal DHEA (marketed as prasterone) takes a different tack. DHEA is a precursor hormone that vaginal cells convert locally into estrogen and other active steroids. A large trial found that after 12 weeks, intravaginal DHEA significantly improved vaginal cell composition, lowered vaginal pH, and reduced both pain during sex and vaginal dryness compared to placebo. Physical exam findings like vaginal secretions, tissue thickness, and color improved by roughly 86% to 121% beyond what placebo did. Critically, blood levels of sex steroids stayed within normal postmenopausal range throughout.²⁶ Because the conversion happens locally, DHEA can appeal to women who are wary of even the low systemic absorption from vaginal estrogen.

Breast Cancer Survivors Face a Harder Decision

GSM hits breast cancer survivors particularly hard, because the very treatments that reduce cancer recurrence, especially aromatase inhibitors, make GSM symptoms worse by further suppressing estrogen. Non-hormonal options like moisturizers and lubricants are always the starting point. When those fail, the decision about whether to use any hormonal approach gets complicated.²⁷

Observational data suggest that low-dose vaginal estrogen is relatively safe in breast cancer survivors taking tamoxifen, because tamoxifen competes for the estrogen receptor and may neutralize any small rise in circulating estradiol. However, for women on aromatase inhibitors the picture is more troubling: prospective trial data show that even vaginal estradiol tablets can raise systemic estradiol levels enough to partially reverse the suppression the aromatase inhibitor is supposed to achieve.²⁸ Current guidance says the decision must be individualized and made jointly with a woman’s oncologist, starting with the lowest effective dose if any vaginal hormone is used.

Intravaginal DHEA and ultra-low-dose estradiol inserts are among the options that produce less systemic absorption and are sometimes considered in severe cases after shared decision-making.²⁹ Ospemifene, because it acts as an anti-estrogen in breast tissue, is also being studied in this context, although its concurrent use with tamoxifen is currently not recommended, and safety data specifically in women with a history of breast cancer remain limited.³⁰

Laser and Radiofrequency Treatments

Vaginal laser and radiofrequency devices have generated enormous interest and equally enormous controversy. The idea is that controlled heat delivery stimulates collagen remodeling and blood-vessel growth in vaginal tissue, restoring some of what estrogen loss took away. Retrospective reviews report improvement in GSM symptoms and sexual function, high patient satisfaction, and mostly minor side effects like temporary discomfort or discharge.³¹

The US Food and Drug Administration issued a safety communication warning against marketing these devices for GSM, citing a lack of adequate evidence. A committee opinion from the International Urogynecological Association echoed the need for well-designed controlled trials before any recommendation could be made.³² A later review pushed back on the FDA’s stance, arguing that most reported “adverse events” actually represented a lack of treatment effect rather than harm, and that the available data on benefits and low risk of complications made laser therapy reasonable with proper counseling.³³ The practical upshot for now: energy-based devices may help some women, but they are not yet backed by the rigorous trial data that hormonal and non-hormonal standard treatments have. Cost is high, insurance rarely covers them, and quality varies by provider.

How GSM Is Assessed in the Clinic

Diagnosis of GSM is mostly clinical: a provider asks about symptoms and performs a physical exam. But there are measurable markers. The FDA has suggested tracking changes in symptom severity, vaginal pH, and the vaginal maturation index (VMI), which reflects how estrogen-deprived the vaginal cells look under a microscope. In current practice, clinicians more commonly use tools like a visual analog scale for symptom severity, the vaginal health index (a standardized physical exam scoring system), and the female sexual function index (a validated questionnaire).³⁴ For most women, no special testing is needed. If you are having symptoms, describing them to your provider is the main diagnostic step.

Probiotics and the Vaginal Microbiome Frontier

Given the central role of Lactobacillus loss in GSM, researchers are exploring whether probiotics could help restore a healthier vaginal environment. Early work suggests the mechanism may be complex. Probiotics containing Lactobacillus species could promote vaginal acidity and microbiome balance, but the improvements in sexual function seen in some trials may come from systemic effects like reduced inflammation or changes in gut-brain signaling rather than direct vaginal colonization.³⁵

Meanwhile, researchers are isolating new Lactobacillus strains directly from postmenopausal vaginal fluid, characterizing their ability to survive in the body and fight off harmful bacteria. Recent lab work identified eight new strains with strong antibacterial activity, good acid and bile resistance, and anti-inflammatory properties in cell models, all without showing signs of toxicity or harboring dangerous genes.³⁶ These strains are candidates for future drug development, though the leap from promising lab characteristics to a product that reliably treats GSM in real women is a long one. The broader research direction, however, feels genuinely promising: if a probiotic could be designed to recolonize the postmenopausal vagina with protective bacteria, it could address a root cause of GSM rather than just supplementing the missing hormone.